Retirement Group’s Travere Therapeutics TVTX Stock Holding History

Retirement Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-700	Closed	-$16K	–	819
2023 Q1	$16K	Buy	+700	New	+$14.9K	0.01%	338

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Retirement Group's TVTX Position: Q2 2023 in Review

Retirement Group sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 700 shares — an estimated $16K sold.

Retirement Group first reported a position in TVTX in Q1 2023 and held it in 1 quarter. The position peaked at $16K in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Retirement Group reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Retirement Group sold 700 Travere Therapeutics shares in Q2 2023, an estimated $16K.
Retirement Group first reported a position in Travere Therapeutics in Q1 2023 and held it in 1 quarter.
Retirement Group's Travere Therapeutics position peaked at $16K in Q1 2023.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Retirement Group's 13F filing for Q2 2023, filed 15 Aug 2023.